FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

| Machinatan  | D C  | 20540 |  |
|-------------|------|-------|--|
| Nashington, | D.C. | 20049 |  |

| <b>STATEMENT</b> | OF CHANGES | S IN BENEFICIAL | <b>OWNERSHIP</b> |
|------------------|------------|-----------------|------------------|

| OMB APPROVAL             |           |  |  |  |  |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|--|--|--|--|
| OMB Number:              | 3235-0287 |  |  |  |  |  |  |  |  |  |  |
| Estimated average burden |           |  |  |  |  |  |  |  |  |  |  |
| hours per response:      | 0.5       |  |  |  |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Ouimette Mike       |   |  |                 |                                 | 2. Issuer Name and Ticker or Trading Symbol PLIANT THERAPEUTICS, INC. [ PLRX ]  |   |                                      |                                  |                 |  |  | heck all<br>D | onship of Reportin<br>all applicable)<br>Director<br>Officer (give title |   | rson(s) to Is  10% Ov Other (s                 | wner   |  |            |  |
|---|---|--|-----------------|---------------------------------|---|---|--------------------------------------|----------------------------------|-----------------|--|--|---------------|--|---|--|--|--|------------|--|
| (Last)  | (Fir  | est) (MAPEUTICS, IN                        | Middle)         |                                 |   | 3. Date of Earliest Transaction (Month/Day/Year) 03/29/2023 |                                      |                                  |                 |  |  |               | A bo   | elow) eneral Couns  |  | below)   | ·  |            |  |
| 260 LITTLEFIELD AVENUE  |   |  |                 |                                 | 4. If <i>I</i>  | 4. If Amendment, Date of Original Filed (Month/Day/Year)    |                                      |                                  |                 |  |  |               |  | 6. Individual or Joint/Group Filing (Check Applicable Line) |  |  |  |            |  |
| (Street) SOUTH FRANCE   | $C_{2}$   | Λ 9  | 4080            |                                 |   |   |                                      |                                  |                 |  |  |               |  |   | F  | orm filed by On<br>orm filed by Mo<br>erson                              |  | •          |  |
| (City)  | (St   | ate) (Z                                    | Zip)            |                                 | Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |   |                                      |                                  |                 |  |  |               |  | nded to   |  |  |  |            |  |
|   |   | Table                                      | I - No          | n-Deriva                        | tive S  | Secui   | rities                               | Acq                              | uired,          | Dis  | posed of   | , or l        | Ben  | efici   | ally O   | vned   |  |            |  |
| 1. Title of Security (Instr. 3)  2. Transac Date (Month/Date) |   |  | Execution Date, |                                 |   |   | es Acquired (A)<br>Of (D) (Instr. 3, |                                  |                 | nd Se<br>Be<br>Ow  | Securities For Exemple 1 For Formula Following (I) |               | n: Direct<br>or Indirect<br>nstr. 4)                                     | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership         |  |  |  |            |  |
|   |   |  |                 |                                 |   |   |                                      | Code                             | v               | Amount   | (A<br>(D   | () or<br>()   | Price  | Tra   | Reported<br>Transaction(s)<br>(Instr. 3 and 4) |  |  | (Instr. 4) |  |
| Common  | Common Stock  |  | 03/29/2         | /2023                           |   |   | A                                    |                                  |                 | 13,593 <sup>(1)</sup> A  |  | \$0.0         | 58,540   |   |  | D  |  |            |  |
|   |   | Tal  |                 |                                 |   |   |                                      |                                  |                 |  | osed of, convertib                                 |               |  |   |  | ned  |  |            |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)           | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | if any          | emed<br>ion Date,<br>/Day/Year) |   | Transaction of Code (Instr. Derivative                      |                                      | Expiration Date (Month/Day/Year) |                 | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Ins<br>3 and 4) |  | f<br>9        | 8. Price<br>Derivati<br>Security<br>(Instr. 5                            | ve derivative<br>Securities                                 | у  | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |            |  |
|   |   |  |                 |                                 | Code  | v   | (A)                                  | (D)                              | Date<br>Exercis | able   | Expiration<br>Date                                 | Title         | or<br>Nur<br>of  | ount<br>nber<br>ires  |  |  |  |            |  |

## **Explanation of Responses:**

1. On July 28, 2022, the Reporting Person was granted 54,375 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 13,593 shares.

## Remarks:

/s/ Mike Ouimette

03/31/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.